Pulse Biosciences reports 86% nodule volume reduction in PRECISE-BTN study
Pulse Biosciences released interim six-month results from its PRECISE-BTN study showing significant nodule shrinkage and symptom relief without serious adverse events, which may support the commercial adoption of its nsPFA technology.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed